HIV Infection Is Associated With Diffusing Capacity Impairment in Women

Fitzpatrick, Meghan E. MD*; Gingo, Matthew R. MD, MS*; Kessinger, Cathy RN*; Lucht, Lorrie BS*; Kleerup, Eric MD; Greenblatt, Ruth M. MD‡,§,‖; Claman, David MD§; Ponath, Claudia MA§; Fong, Serena BS§; Huang, Laurence MD, MAS§; Morris, Alison MD, MS*,¶

JAIDS Journal of Acquired Immune Deficiency Syndromes:
doi: 10.1097/QAI.0b013e3182a9213a
Brief Report: Clinical Science
Abstract

Abstract: Respiratory dysfunction is common with HIV infection, but few studies have directly assessed whether HIV remains an independent risk factor for pulmonary function abnormalities in the antiretroviral therapy era. Additionally, few studies have focused on pulmonary outcomes in HIV+ women. We tested associations between risk factors for respiratory dysfunction and pulmonary outcomes in 63 HIV+ and 36 HIV-uninfected women enrolled in the Women's Interagency HIV Study. Diffusing capacity (DLCO) was significantly lower in HIV+ women (65.5% predicted vs. 72.7% predicted, P = 0.01), and self-reported dyspnea in HIV+ participants was associated with both DLCO impairment and airflow obstruction. Providers should be aware that DLCO impairment is common in HIV infection, and that either DLCO impairment or airflow obstruction may cause respiratory symptoms in this population.

Author Information

*Department of Medicine, University of Pittsburgh, Pittsburgh, PA;

Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA;

Department of Clinical Pharmacy, School of Pharmacy, University of California, San Francisco, CA;

Departments of §Medicine;

Epidemiology and Biostatistics, School of Medicine, University of California, San Francisco, CA; and

Department of Immunology, University of Pittsburgh, Pittsburgh, PA.

Correspondence to: Alison Morris, MD, MS, Departments of Medicine and Immunology, University of Pittsburgh, 3459 Fifth Avenue, 628 NW, Pittsburgh, PA 15213 (e-mail: morrisa@upmc.edu).

Supported by the National Heart, Lung, and Blood Institute Grants F32 HL114426 (to M.E.F.), K23 HL108697 (to M.R.G.); K24 HL 087713 (to L.H.), and R01 HL083461, HL083461S, and HL090339 (to A.M.); the National Institute of Allergy and Infectious Diseases Grants UO1-AI-35004, UO1-AI-31834, UO1-AI-34994, UO1-AI-34989, UO1-AI-34993, and UO1-AI-42590 [to Women's Interagency HIV Study (WIHS)]; the Eunice Kennedy Shriver National Institute of Child Health and Human Development Grant UO1-HD-32632 (to WIHS); the National Cancer Institute; the National Institute on Drug Abuse; the National Institute on Deafness and Other Communication Disorders; and the National Center for Research Resources (UCSF-CTSI) Grant UL1 RR024131 (to WIHS).

The contents of this publication are solely the responsibility of the authors and do not necessarily represent the official views of the National Institutes of Health. The authors have no conflicts of interest to disclose.

M.E.F. and M.R.G. contributed equally.

Received April 21, 2013

Accepted July 25, 2013

© 2013 by Lippincott Williams & Wilkins